The multifunctional role of Notch signaling in multiple myeloma

Abstract

Multiple myeloma (MM) is a hematologic cancer characterized by uncontrolled growth of malignant plasma cells in the bone marrow and currently is incurable. The bone marrow microenvironment plays a critical role in MM. MM cells reside in specialized niches where they interact with multiple marrow cell types, transforming the bone/bone marrow compartment into an ideal microenvironment for the migration, proliferation, and survival of MM cells. In addition, MM cells interact with bone cells to stimulate bone destruction and promote the development of bone lesions that rarely heal. In this review, we discuss how Notch signals facilitate the communication between adjacent MM cells and between MM cells and bone/bone marrow cells and shape the microenvironment to favor MM progression and bone disease. We also address the potential and therapeutic approaches used to target Notch signaling in MM.

Keywords

Notch / tumor microenvironment / multiple myeloma / bone / osteocytes / osteoclasts / osteoblasts / γ-secretase inhibitors.

References

[1] Bianchi G.Pathogenesis beyond the cancer clone(s) in multiple myeloma.Blood2015;125:3049-58 PMCID:PMC4432002

[2] Rajkumar SV.Myeloma today: Disease definitions and treatment advances.Am J Hematol2016;91:90-100 PMCID:PMC4715763

[3] Kyle RA.Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma.Leukemia2009;23:3-9 PMCID:PMC2627786

[4] Mateos MV.Smoldering multiple myeloma: Who and when to treat.Clin Lymphoma Myeloma Leuk2017;17:716-22

[5] Mouhieddine TH,Ghobrial IM.Monoclonal gammopathy of undetermined significance.Blood2019;133:2484-94

[6] Zingone A.Pathogenesis of monoclonal gammopathy of undetermined significance and progression to multiple myeloma.Semin Hematol2011;48:4-12 PMCID:PMC3040450

[7] Rajkumar SV,Mateos MV.Smoldering multiple myeloma.Blood2015;125:3069-75 PMCID:PMC4432003

[8] Gundesen MT,Moeller HEH.Plasma cell leukemia: Definition, presentation, and treatment.Curr Oncol Rep2019;21:8 PMCID:PMC6349791

[9] Terpos E,Gavriatopoulou M.Pathogenesis of bone disease in multiple myeloma: from bench to bedside.Blood Cancer J2018;8:7 PMCID:PMC5802524

[10] Silbermann R.Myeloma bone disease: Pathophysiology and management.J Bone Oncol2013;2:59-69 PMCID:PMC4723362

[11] Delgado-calle J.Osteocytes and their messengers as targets for the treatment of multiple myeloma.Clinic Rev Bone Miner Metab2017;15:49-56

[12] Macedo F,Pinho F.Bone metastases: An overview.Oncol Rev2017;11:321 PMCID:PMC5444408

[13] Delgado-Calle J,Atkinson EG.Aplidin (plitidepsin) is a novel anti-myeloma agent with potent anti-resorptive activity mediated by direct effects on osteoclasts.Oncotarget2019;10:2709-21 PMCID:PMC6505631

[14] Raje N,Willenbacher W.Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study.Lancet Oncol2018;19:370-81

[15] Delgado-Calle J,Cregor MD.Genetic deletion of Sost or pharmacological inhibition of sclerostin prevent multiple myeloma-induced bone disease without affecting tumor growth.Leukemia2017;31:2686-94 PMCID:PMC5699973

[16] McDonald MM,Youlten SE.Inhibiting the osteocyte-specific protein sclerostin increases bone mass and fracture resistance in multiple myeloma.Blood2017;129:3452-64 PMCID:PMC5492093

[17] Eda H,Wein MN.Regulation of sclerostin expression in multiple myeloma by Dkk-1: A potential therapeutic strategy for myeloma bone disease.J Bone Miner Res2016;31:1225-34 PMCID:PMC5002355

[18] Croucher PI,Martin TJ.Bone metastasis: the importance of the neighbourhood.Nat Rev Cancer2016;16:373-86

[19] Hideshima T.Signaling pathway mediating myeloma cell growth and survival.Cancers (Basel)2021;13:216 PMCID:PMC7827005

[20] Lomas OC,Ghobrial IM.The microenvironment in myeloma.Curr Opin Oncol2020;32:170-5

[21] Kawano Y,Manier S.Targeting the bone marrow microenvironment in multiple myeloma.Immunol Rev2015;263:160-72

[22] Siebel C.Notch signaling in development, tissue homeostasis, and Disease.Physiol Rev2017;97:1235-94

[23] Bray SJ.Notch signalling in context.Nat Rev Mol Cell Biol2016;17:722-35

[24] Kopan R.The canonical Notch signaling pathway: unfolding the activation mechanism.Cell2009;137:216-33 PMCID:PMC2827930

[25] Colombo M,Garavelli S.Notch signaling deregulation in multiple myeloma: A rational molecular target.Oncotarget2015;6:26826-40 PMCID:PMC4694956

[26] Komatsu H,Larkins-Ford J.OSM-11 facilitates LIN-12 Notch signaling during Caenorhabditis elegans vulval development.PLoS Biol2008;6:e196 PMCID:PMC2504490

[27] Cordle J,Tay JZ.A conserved face of the Jagged/Serrate DSL domain is involved in Notch trans-activation and cis-inhibition.Nat Struct Mol Biol2008;15:849-57 PMCID:PMC2669539

[28] Cordle J,Stacey M.Localization of the delta-like-1-binding site in human Notch-1 and its modulation by calcium affinity.J Biol Chem2008;283:11785-93

[29] Raya A,Rodríguez-Esteban C.Notch activity acts as a sensor for extracellular calcium during vertebrate left-right determination.Nature2004;427:121-8

[30] Bray SJ.Notch signalling: a simple pathway becomes complex.Nat Rev Mol Cell Biol2006;7:678-89

[31] D'Souza B,Weinmaster G.The many facets of Notch ligands.Oncogene2008;27:5148-67 PMCID:PMC2791526

[32] Tetering G, Vooijs M. Proteolytic cleavage of Notch: "HIT and RUN".Curr Mol Med2011;11:255-69 PMCID:PMC4050734

[33] Kitagawa M.Notch signalling in the nucleus: roles of Mastermind-like (MAML) transcriptional coactivators.J Biochem2016;159:287-94

[34] Kovall RA.More complicated than it looks: assembly of Notch pathway transcription complexes.Oncogene2008;27:5099-109

[35] Borggrefe T.The Notch signaling pathway: Transcriptional regulation at Notch target genes.Cell Mol Life Sci2009;66:1631-46

[36] Aster JC,Blacklow SC.The varied roles of Notch in cancer.Annu Rev Pathol2017;12:245-75 PMCID:PMC5933931

[37] Nowell CS.Notch as a tumour suppressor.Nat Rev Cancer2017;17:145-59

[38] Colombo M,Platonova N.Notch-directed microenvironment reprogramming in myeloma: a single path to multiple outcomes.Leukemia2013;27:1009-18

[39] De Vos J,Tarte K.Identifying intercellular signaling genes expressed in malignant plasma cells by using complementary DNA arrays.Blood2001;98:771-80

[40] Jundt F,Anagnostopoulos I.Jagged1-induced Notch signaling drives proliferation of multiple myeloma cells.Blood2004;103:3511-5

[41] Skrtić A,Krišto DR,Ivanković D.Immunohistochemical analysis of NOTCH1 and JAGGED1 expression in multiple myeloma and monoclonal gammopathy of undetermined significance.Hum Pathol2010;41:1702-10

[42] Houde C,Song L.Overexpression of the NOTCH ligand JAG2 in malignant plasma cells from multiple myeloma patients and cell lines.Blood2004;104:3697-704

[43] Delgado-Calle J,Cregor MD.Bidirectional Notch signaling and Osteocyte-derived factors in the bone marrow microenvironment promote tumor cell proliferation and bone destruction in multiple myeloma.Cancer Res2016;76:1089-100 PMCID:PMC4775415

[44] Zhan F,Colla S.The molecular classification of multiple myeloma.Blood2006;108:2020-8 PMCID:PMC1895543

[45] Stralen E, van de Wetering M, Agnelli L, Neri A, Clevers HC, Bast BJ. Identification of primary MAFB target genes in multiple myeloma.Exp Hematol2009;37:78-86

[46] Ordoñez R,Russiñol N.Chromatin activation as a unifying principle underlying pathogenic mechanisms in multiple myeloma.Genome Res2020;30:1217-27 PMCID:PMC7545147

[47] Jundt F,Anagnostopoulos I.Jagged1-induced Notch signaling drives proliferation of multiple myeloma cells.Blood2004;103:3511-5.

[48] Pisklakova A,Ozerova M,Sullivan DM.Anti-myeloma effect of pharmacological inhibition of Notch/gamma-secretase with RO4929097 is mediated by modulation of tumor microenvironment.Cancer Biol Ther2016;17:477-85 PMCID:PMC4910908

[49] Schwarzer R,Godau J.Notch pathway inhibition controls myeloma bone disease in the murine MOPC315.BM model.Blood Cancer J2014;4:e217. PMCID:PMC4080208

[50] Nefedova Y,Bolick SC,Gabrilovich DI.Inhibition of Notch signaling induces apoptosis of myeloma cells and enhances sensitivity to chemotherapy.Blood2008;111:2220-9

[51] Ramakrishnan V,Haug J.MRK003, a γ-secretase inhibitor exhibits promising in vitro pre-clinical activity in multiple myeloma and non-Hodgkin's lymphoma.Leukemia2012;26:340-8 PMCID:PMC4384189

[52] Zweidler-McKay PA,Xu L.Notch signaling is a potent inducer of growth arrest and apoptosis in a wide range of B-cell malignancies.Blood2005;106:3898-906 PMCID:PMC1895093

[53] Colombo M,Bulfamante G.Multiple myeloma-derived Jagged ligands increases autocrine and paracrine interleukin-6 expression in bone marrow niche.Oncotarget2016;7:56013-29 PMCID:PMC5302893

[54] Li M,Clifton N.Combined inhibition of Notch signaling and Bcl-2/Bcl-xL results in synergistic antimyeloma effect.Mol Cancer Ther2010;9:3200-9 PMCID:PMC3058809

[55] Colombo M,Giannandrea D,Basile A.Re-establishing apoptosis competence in bone associated cancers via communicative reprogramming induced through Notch signaling inhibition.Front Pharmacol2019;10:145 PMCID:PMC6400837

[56] Mirandola L,Colombo M.Anti-Notch treatment prevents multiple myeloma cells localization to the bone marrow via the chemokine system CXCR4/SDF-1.Leukemia2013;27:1558-66

[57] Guo D,Teng Q,Li Y.Notch1 overexpression promotes cell growth and tumor angiogenesis in myeloma.Neoplasma2013;60:33-40

[58] Sabol HM,Kurihara N.Autocrine and paracrine Notch receptor 3 signaling in the myeloma niche stimulates tumor growth and bone destruction.J Bone Miner Res2020;35:98

[59] Chiron D,Descamps G.Critical role of the NOTCH ligand JAG2 in self-renewal of myeloma cells.Blood Cells Mol Dis2012;48:247-53

[60] Berenstein R,Waechter M.Multiple myeloma cells modify VEGF/IL-6 levels and osteogenic potential of bone marrow stromal cells via Notch/miR-223.Mol Carcinog2016;55:1927-39

[61] Xu D,Xu S.Dll1/Notch activation accelerates multiple myeloma disease development by promoting CD138+ MM-cell proliferation.Leukemia2012;26:1402-5

[62] Xu D,De Bruyne E.Dll1/Notch activation contributes to bortezomib resistance by upregulating CYP1A1 in multiple myeloma.Biochem Biophys Res Commun2012;428:518-24

[63] Yin L.Chondroitin synthase 1 is a key molecule in myeloma cell-osteoclast interactions.J Biol Chem2005;280:15666-72

[64] Hu J,Lu Q.Antiproliferative effects of γ-secretase inhibitor, a Notch signalling inhibitor, in multiple myeloma cells and its molecular mechanism of action.J Int Med Res2013;41:1017-26

[65] Das DS,Ray A.Blockade of deubiquitylating enzyme USP1 inhibits DNA repair and triggers apoptosis in multiple myeloma cells.Clin Cancer Res2017;23:4280-9 PMCID:PMC5540781

[66] Wang Y,Huang F.Synthesis of sophocarpine triflorohydrazone and its proliferation inhibition and apoptosis induction activity in myeloma cells through Notch3-p53 signaling activation.Environ Toxicol2021;36:484-90

[67] Bai Y.Updates to the drug-resistant mechanism of proteasome inhibitors in multiple myeloma.Asia Pac J Clin Oncol2021;17:29-35

[68] Abdi J,Chang H.Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms.Oncotarget2013;4:2186-207 PMCID:PMC3926819

[69] Nefedova Y,Alsina M,Gabrilovich DI.Involvement of Notch-1 signaling in bone marrow stroma-mediated de novo drug resistance of myeloma and other malignant lymphoid cell lines.Blood2004;103:3503-10

[70] Colombo M,Mazzola M.Multiple myeloma exploits Jagged1 and Jagged2 to promote intrinsic and bone marrow-dependent drug resistance.Haematologica2020;105:1925-36 PMCID:PMC7327642

[71] Muguruma Y,Warita T.Jagged1-induced Notch activation contributes to the acquisition of bortezomib resistance in myeloma cells.Blood Cancer J2017;7:650 PMCID:PMC5802593

[72] Ding Y.Notch increased vitronection adhesion protects myeloma cells from drug induced apoptosis.Biochem Biophys Res Commun2015;467:717-22

[73] Vacca A,Roncali L.Bone marrow angiogenesis and progression in multiple myeloma.Br J Haematol1994;87:503-8

[74] Scavelli C,Cirulli T.Vasculogenic mimicry by bone marrow macrophages in patients with multiple myeloma.Oncogene2008;27:663-74

[75] Ria R,Racanelli V.Anti-VEGF drugs in the treatment of multiple myeloma patients.J Clin Med2020;9:1765 PMCID:PMC7355441

[76] Vacca A.Bone marrow angiogenesis in multiple myeloma.Leukemia2006;20:193-9

[77] Ria R,Merchionne F,Dammacco F.Vascular endothelial growth factor and its receptors in multiple myeloma.Leukemia2003;17:1961-6

[78] Palano MT,Platonova N.Jagged ligands enhance the pro-angiogenic activity of multiple myeloma cells.Cancers (Basel)2020;12:2600 PMCID:PMC7565520

[79] Saltarella I,Lamanuzzi A.Homotypic and heterotypic activation of the Notch pathway in multiple myeloma-enhanced angiogenesis: A novel therapeutic target?.Neoplasia2019;21:93-105 PMCID:PMC6282459

[80] Mulcrone PL,Petrusca DN,Delgado-Calle J.Osteocyte Vegf-a contributes to myeloma-associated angiogenesis and is regulated by Fgf23.Sci Rep2020;10:17319 PMCID:PMC7560700

[81] Allen MR.Bone modeling and remodeling. In: Burr DB, Allen MR, editors. Basic and Applied Bone Biology. Netherlands: Elsevier; 2014. p. 75-90.

[82] Delgado-Calle J.Osteocytes and skeletal pathophysiology.Curr Mol Biol Rep2015;1:157-67 PMCID:PMC4673661

[83] Canalis E.Notch in skeletal physiology and disease.Osteoporos Int2018;29:2611-21 PMCID:PMC6494455

[84] Bai S,Zou W.NOTCH1 regulates osteoclastogenesis directly in osteoclast precursors and indirectly via osteoblast lineage cells.J Biol Chem2008;283:6509-18

[85] Fukushima H,Okamoto F.The association of Notch2 and NF-kappaB accelerates RANKL-induced osteoclastogenesis.Mol Cell Biol2008;28:6402-12 PMCID:PMC2577420

[86] Yamada T,Yamane T.Regulation of osteoclast development by Notch signaling directed to osteoclast precursors and through stromal cells.Blood2003;101:2227-34

[87] Zanotti S,Stadmeyer L,Radtke F.Notch inhibits osteoblast differentiation and causes osteopenia.Endocrinology2008;149:3890-9 PMCID:PMC2488209

[88] Hilton MJ,Wu X.Notch signaling maintains bone marrow mesenchymal progenitors by suppressing osteoblast differentiation.Nat Med2008;14:306-14 PMCID:PMC2740725

[89] Deregowski V,Priest L,Canalis E.Notch 1 overexpression inhibits osteoblastogenesis by suppressing Wnt/beta-catenin but not bone morphogenetic protein signaling.J Biol Chem2006;281:6203-10

[90] Sciaudone M,Priest L,Canalis E.Notch 1 impairs osteoblastic cell differentiation.Endocrinology2003;144:5631-9

[91] Tezuka K,Watanabe N.Stimulation of osteoblastic cell differentiation by Notch.J Bone Miner Res2002;17:231-9

[92] Canalis E,Boskey A,Kranz L.Notch signaling in osteocytes differentially regulates cancellous and cortical bone remodeling.J Biol Chem2013;288:25614-25 PMCID:PMC3757222

[93] Liu P,Ma M.Anabolic actions of Notch on mature bone.Proc Natl Acad Sci U S A2016;113:E2152-61 PMCID:PMC4839423

[94] Marino S,Roodman GD.Therapeutic targets in myeloma bone disease.Br J Pharmacol2019;

[95] Silbermann R.Current controversies in the management of myeloma bone disease.J Cell Physiol2016;231:2374-9

[96] Raje N.Advances in the biology and treatment of bone disease in multiple myeloma.Clin Cancer Res2011;17:1278-86

[97] Roodman GD.Pathogenesis of myeloma bone disease.Leukemia2009;23:435-41

[98] Colombo M,Mirandola L.Notch signaling drives multiple myeloma induced osteoclastogenesis.Oncotarget2014;5:10393-406 PMCID:PMC4279381

[99] Xiong J,Jilka RL,Manolagas SC.Matrix-embedded cells control osteoclast formation.Nat Med2011;17:1235-41 PMCID:PMC3192296

[100] Nakashima T,Fukunaga T.Evidence for osteocyte regulation of bone homeostasis through RANKL expression.Nat Med2011;17:1231-4

[101] Xu S,Buckle C.Impaired osteogenic differentiation of mesenchymal stem cells derived from multiple myeloma patients is associated with a blockade in the deactivation of the Notch signaling pathway.Leukemia2012;26:2546-9

[102] Guo J,Zhao Y.Lenalidomide restores the osteogenic differentiation of bone marrow mesenchymal stem cells from multiple myeloma patients via deactivating Notch signaling pathway.Oncotarget2017;8:55405-21 PMCID:PMC5589668

[103] Canalis E,Schilling L.Canonical Notch activation in osteocytes causes osteopetrosis.Am J Physiol Endocrinol Metab2016;310:E171-82 PMCID:PMC4719030

[104] Schwarzer R,Acikgoez O.Notch inhibition blocks multiple myeloma cell-induced osteoclast activation.Leukemia2008;22:2273-7

[105] Ferrari A,Nelson JH.Bone-targeted inhibition of Notch signaling blocks tumor growth and prevents bone loss without inducing gut toxicity in immunodeficient and immunocompetent murine models of established multiple myeloma.J Bone Miner Res2019;34:32

[106] Moore G,McClements L.Top Notch targeting strategies in cancer: A detailed overview of recent insights and current perspectives.Cells2020;9:1503 PMCID:PMC7349363

[107] Fabbro D,Murone M.Notch inhibition in cancer: Challenges and opportunities.Chimia (Aarau)2020;74:779-83

[108] Nefedova Y.Mechanisms and clinical prospects of Notch inhibitors in the therapy of hematological malignancies.Drug Resist Updat2008;11:210-8 PMCID:PMC2731237

[109] Kreft AF,Porte A.Recent advances in the identification of gamma-secretase inhibitors to clinically test the Abeta oligomer hypothesis of Alzheimer's disease.J Med Chem2009;52:6169-88

[110] Imbimbo BP.Therapeutic potential of gamma-secretase inhibitors and modulators.Curr Top Med Chem2008;8:54-61

[111] Searfoss GH,Calligaro DO.Adipsin, a biomarker of gastrointestinal toxicity mediated by a functional gamma-secretase inhibitor.J Biol Chem2003;278:46107-16

[112] Lehal R,Vigolo M.Pharmacological disruption of the Notch transcription factor complex.Proc Natl Acad Sci U S A2020;117:16292-301 PMCID:PMC7368267

[113] Pont MJ,Cole GO.γ-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma.Blood2019;134:1585-97 PMCID:PMC6871311